TScan Therapeutics, Inc.

NasdaqGM:TCRX Stock Report

Market Cap: US$219.9m

TScan Therapeutics Valuation

Is TCRX undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

1/6

Valuation Score 1/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of TCRX when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate TCRX's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate TCRX's fair value for valuation analysis.


Key Valuation Metric

Which metric is best to use when looking at relative valuation for TCRX?

Key metric: As TCRX is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for TCRX. This is calculated by dividing TCRX's market cap by their current revenue.
What is TCRX's PS Ratio?
PS Ratio22.5x
SalesUS$9.36m
Market CapUS$219.89m

Price to Sales Ratio vs Peers

How does TCRX's PS Ratio compare to its peers?

The above table shows the PS ratio for TCRX vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PSEstimated GrowthMarket Cap
Peer Average2.3x
ADCT ADC Therapeutics
2.7x31.0%US$191.4m
ANIK Anika Therapeutics
1.6x-13.3%US$251.6m
TSVT 2seventy bio
3.6x21.8%US$160.4m
MGNX MacroGenics
1.4x-14.3%US$205.9m
TCRX TScan Therapeutics
22.5x65.7%US$219.9m

Price-To-Sales vs Peers: TCRX is expensive based on its Price-To-Sales Ratio (22.5x) compared to the peer average (2.3x).


Price to Sales Ratio vs Industry

How does TCRX's PS Ratio compare vs other companies in the US Biotechs Industry?

131 CompaniesPrice / SalesEstimated GrowthMarket Cap
GILD Gilead Sciences
4x2.4%US$110.46b
BIIB Biogen
2.4x1.3%US$22.73b
MRNA Moderna
2.9x6.8%US$14.22b
INCY Incyte
3.3x8.9%US$13.69b
TCRX 22.5xIndustry Avg. 9.6xNo. of Companies131PS01632486480+
131 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Sales vs Industry: TCRX is expensive based on its Price-To-Sales Ratio (22.5x) compared to the US Biotechs industry average (10.1x).


Price to Sales Ratio vs Fair Ratio

What is TCRX's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

TCRX PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio22.5x
Fair PS Ratio0.03x

Price-To-Sales vs Fair Ratio: TCRX is expensive based on its Price-To-Sales Ratio (22.5x) compared to the estimated Fair Price-To-Sales Ratio (0x).


Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst TCRX forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentUS$3.94
US$12.57
+219.1%
13.3%US$15.00US$10.00n/a7
Nov ’25US$4.95
US$12.57
+154.0%
13.3%US$15.00US$10.00n/a7
Oct ’25US$4.98
US$12.57
+152.4%
13.3%US$15.00US$10.00n/a7
Sep ’25US$5.63
US$12.57
+123.3%
13.3%US$15.00US$10.00n/a7
Aug ’25US$6.83
US$12.29
+79.9%
15.5%US$15.00US$10.00n/a7
Jul ’25US$5.93
US$12.29
+107.2%
15.5%US$15.00US$10.00n/a7
Jun ’25US$8.55
US$12.29
+43.7%
15.5%US$15.00US$10.00n/a7
May ’25US$8.62
US$11.60
+34.6%
20.8%US$15.00US$9.00n/a5
Apr ’25US$8.01
US$11.60
+44.8%
20.8%US$15.00US$9.00n/a5
Mar ’25US$7.20
US$10.80
+50.0%
28.9%US$15.00US$7.00n/a5
Feb ’25US$5.15
US$10.80
+109.7%
28.9%US$15.00US$7.00n/a5
Jan ’25US$5.83
US$10.80
+85.2%
28.9%US$15.00US$7.00n/a5
Dec ’24US$6.48
US$10.60
+63.6%
30.8%US$15.00US$7.00n/a5
Nov ’24US$3.62
US$10.75
+197.0%
35.7%US$15.00US$6.00US$4.954
Oct ’24US$2.56
US$10.75
+319.9%
35.7%US$15.00US$6.00US$4.984
Sep ’24US$2.46
US$10.75
+337.0%
35.7%US$15.00US$6.00US$5.634
Aug ’24US$2.19
US$10.75
+390.9%
35.7%US$15.00US$6.00US$6.834
Jul ’24US$2.50
US$10.75
+330.0%
35.7%US$15.00US$6.00US$5.934
Jun ’24US$2.31
US$10.50
+354.5%
38.4%US$15.00US$6.00US$8.554
May ’24US$1.64
US$10.50
+540.2%
38.4%US$15.00US$6.00US$8.624
Apr ’24US$2.10
US$10.50
+400.0%
38.4%US$15.00US$6.00US$8.014
Mar ’24US$3.15
US$10.75
+241.3%
35.7%US$15.00US$6.00US$7.204
Feb ’24US$1.81
US$14.00
+673.5%
38.1%US$21.00US$6.00US$5.154
Jan ’24US$1.55
US$14.00
+803.2%
38.1%US$21.00US$6.00US$5.834
Dec ’23US$2.16
US$14.00
+548.1%
38.1%US$21.00US$6.00US$6.484
Nov ’23US$2.76
US$14.00
+408.2%
38.1%US$21.00US$6.00US$3.624

Analyst Forecast: Target price is more than 20% higher than the current share price and analysts are within a statistically confident range of agreement.


Discover undervalued companies